BMY Sep 2024 46.000 call
| Previous close | 1.1600 |
| Open | 0.9500 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 46.00 |
| Expiry date | 2024-09-20 |
| Day's range | 0.9500 - 1.2000 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
ZacksBristol Myers (BMY) Updates Action Date for Subcutaneous Opdivo
The FDA assigns a new target action date of Dec 29, 2024, to Bristol Myers (BMY) BLA for subcutaneous nivolumab (nivolumab and hyaluronidase).
ReutersBristol Myers, Sanofi liability in Hawaii Plavix case grows to $916 million
A judge in Hawaii on Tuesday ordered Bristol Myers Squibb and Sanofi to pay more than $916 million to the state for failing to warn non-white patients of health risks from its blood thinner Plavix, up from an earlier judgment of $834 million. The ruling from Judge James Ashford, of Hawaii's First Circuit Court, follows a non-jury trial held last fall. It was the second trial in the case, after the state's Supreme Court found that the judge in the first trial that resulted in the $834 million award had made a legal error.
Business WireBristol Myers Squibb Announces 10-Year Strategy to Reach More Patients in Low- and Middle-Income Countries
PRINCETON, N.J., May 22, 2024--Bristol Myers Squibb Announces 10-Year Strategy to Reach More Patients in Low- and Middle-Income Countries
